ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor

Blood

Volumn 118, Issue 18, 2011, Pages 4910-4918

  Torrano, Veronica ^a   Procter, Julia ^a   Cardus, Penny ^a   Greaves, Mel ^a   Ford, Anthony M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; LIGAND; PROTEIN BCL XL; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL SURFACE; CELL SURVIVAL; CLONE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRELEUKEMIA; PRIORITY JOURNAL; STEM CELL; UPREGULATION;

EID: 80855144788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-354266     Document Type: Article

References (50)

1. Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995; 85(12):3662-3670.
2. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9(12):1985-1989. (Pubitemid 26023779)
3. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A. 1998;95(8): 4584-4588. (Pubitemid 28207956)
4. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354(9189):1499-1503. (Pubitemid 29502102)
5. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood. 1999;94(3):1057- 1062.
6. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A. 2002;99(12):8242-8247. (Pubitemid 34651037)
7. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102(7):2321-2333. (Pubitemid 37193565)
8. Andreasson P, Schwaller J, Anastasiadou E, Aster J, Gilliland DG. The expression of ETV6/ CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet. 2001;130(2):93-104. (Pubitemid 33033225)
9. Fischer M, Schwieger M, Horn S, et al. Defining the oncogenic function of the TEL/AML1 (ETV6/ RUNX1) fusion protein in a mouse model. Oncogene. 2005;24(51):7579-7591. (Pubitemid 41638032)
10. Ford AM, Palmi C, Bueno C, et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest. 2009;119(4):826-836.
11. Morrow M, Horton S, Kioussis D, Brady HJ, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood. 2004;103(10):3890- 3896.
12. Tsuzuki S, Seto M, Greaves M, Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci U S A. 2004; 101(22):8443-8448. (Pubitemid 38736594)
13. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-764. (Pubitemid 46582031)
14. Bateman CM, Colman SM, Chaplin T, et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood. 2010;115(17):3553-3558.
15. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330. (Pubitemid 26042836)
16. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996; 93(8):3444-3449. (Pubitemid 26125639)
17. Fenrick R, Amann JM, Lutterbach B, et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol. 1999; 19(10):6566-6574. (Pubitemid 29441841)
18. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene. 1999;18(4): 1015-1022. (Pubitemid 29086278)
19. Guidez F, Petrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood. 2000;96(7):2557-2561.
20. Gunji H, Waga K, Nakamura F, et al. TEL/AML1 shows dominant-negative effects over TEL as well as AML1. Biochem Biophys Res Commun. 2004;322(2):623-630. (Pubitemid 39490348)
21. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88(11):4252-4258. (Pubitemid 26399172)
22. Diakos C, Krapf G, Gerner C, et al. RNAi-mediated silencing of TEL/AML1 reveals a heat-shock proteinand survivin-dependent mechanism for survival. Blood. 2007;109(6):2607-2610. (Pubitemid 46425909)
23. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 2002;21(21):3475-3495. (Pubitemid 34587717)
24. Greaves M. The causation of childhood leukemia: a paradox of progress? Discov Med. 2006;6(31): 24-28.
25. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer- propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319(5861):336- 339.
26. Schindler JW, Van Buren D, Foudi A, et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell. 2009;5(1):43-53.
27. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood. 2004;103(3):1043-1049. (Pubitemid 38129570)
28. Inthal A, Krapf G, Beck D, et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res. 2008; 14(22):7196-7204.
29. van Delft FW, Bellotti T, Luo Z, et al. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol. 2005;130(1):26-35. (Pubitemid 40979129)
30. Luo XM, Maarschalk E, O'Connell RM, Wang P, Yang L, Baltimore D. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood. 2009;113(7):1422-1431.
31. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006; 1(1):241-245.
32. Elliott S, Busse L, McCaffery I, et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods. 2010;352(1): 126-139.
33. Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010;115(21):4254-4263.
34. Shinjo K, Takeshita A, Higuchi M, Ohnishi K, Ohno R. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flow-cytometric assay. Br J Haematol. 1997;96(3):551-558. (Pubitemid 27087242)
35. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008; 141(1):14-31. (Pubitemid 351347536)
36. 0 function of BCL-2 or BCLxL. Cell Cycle. 2008;7(17):2762-2768.
37. Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. Trends Immunol. 2003;24(7):380- 386.
38. Oda A, Sawada K, Druker BJ, et al. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors. Blood. 1998;92(2):443-451. (Pubitemid 28323706)
39. 0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem. 2008; 283(49):34108-34120.
40. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells: from clinic to bench-a critical review. Biochim Biophys Acta. 2010;1806(1):82-95.
41. Morrow M, Samanta A, Kioussis D, Brady HJ, Williams O. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene. 2007;26(30):4404-4414. (Pubitemid 47014465)
42. Bittorf T, Jaster R, Ludtke B, Kamper B, Brock J. Requirement for JAK2 in erythropoietin-induced signalling pathways. Cell Signal. 1997;9(1):85-89. (Pubitemid 27120871)
43. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood. 1999;94(1):87-96. (Pubitemid 29300137)
44. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96(6):2022- 2036.
45. Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999;96(5):2110-2115. (Pubitemid 29117876)
46. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004; 101(41):14907-14912. (Pubitemid 39410773)
47. Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):930-932.
48. Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646-648.
49. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243- 1246.
50. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.